Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Update

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 731,000 shares, an increase of 15.7% from the January 15th total of 631,800 shares. Based on an average trading volume of 1,930,000 shares, the short-interest ratio is currently 0.4 days.

Petros Pharmaceuticals Stock Performance

Shares of NASDAQ:PTPI traded up $0.05 during trading on Monday, hitting $0.29. 107,200,541 shares of the stock were exchanged, compared to its average volume of 383,633. The company has a market capitalization of $2.94 million, a price-to-earnings ratio of -0.06 and a beta of 1.84. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.74 and a current ratio of 0.85. Petros Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $1.76. The company’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.33.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).